计算溶液所需的质量、体积或浓度。
这是演示店铺,请务下单付款,避免造成你的财物损失。
为了获得访问"阿拉丁铁蛋"实时聊天框的流畅支持体验,建议您使用Chrome浏览器或选择360浏览器极速模式(如何切换极速模式?),感谢您选择我们!
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
T411999-1mg |
1mg |
期货 ![]() |
| |
T411999-5mg |
5mg |
期货 ![]() |
| |
T411999-10mg |
10mg |
期货 ![]() |
|
产品名称 | Trastuzumab (anti-HER2) |
---|---|
别名 | 曲妥珠单抗; Herceptin; Recombinant Trastuzumab Antibody; Anti-Human HER2, Humanized Antibody; Trastuzumab (Anti-Human HER2, Humanized Antibody); Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog antibody; Cer |
英文别名 | Herceptin; Recombinant Trastuzumab Antibody; Anti-Human HER2, Humanized Antibody; Trastuzumab (Anti-Human HER2, Humanized Antibody); Verb b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog antibody; Cerb B2/ne |
规格或纯度 | Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated |
特异性 | ERBB2/HER2/CD340 |
应用 | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
反应种属 | Human,Mouse |
抗体类型 | Primary antibody |
---|---|
Format | Whole IgG |
亚型 | Human IgG1 |
轻链亚型 | Kappa |
SDS-PAGE | 150 kDa |
纯化方法 | Protein A purified |
来源 | CHO supernatant |
物理外观 | Liquid |
防腐剂 | No |
浓度 | Lot by Lot |
储存温度 | -80℃储存,避免反复冻融 |
运输条件 | 超低温冰袋运输 |
稳定性与储存 | Store at -80℃ for two years. Avoid freeze/thaw. |
CAS编号和信息 | 180288-69-1 |
Wikipedia | Trastuzumab |
---|---|
IMGT/mAb-DB | 97 |
PubChem SID | 178101775 |
PEP | trastuzumab |
Reactome Reaction | R-HSA-9652277, R-HSA-9665405, R-HSA-9649393, R-HSA-9665696, R-HSA-9665232 |
Reactome Drug | R-ALL-9634466 |
象形图 |
![]() Health Hazard |
---|---|
信号词 | Danger |
危险声明 |
H360: May damage fertility or the unborn child |
预防措施声明 | P280,P405,P501,P203,P318 |
输入批号以搜索COA:
1. Mitri Z, Constantine T, O'Regan R. (2012) The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy.. Chemother Res Pract, 2012 (13): (743193). [PMID:23320171] |
2. Paplomata E, Nahta R. (2018) ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer.. Expert Opin Biol Ther, 18 (3): (335-341). [PMID:29350568] |